Aza-bicyclic compounds and their use as stimulators of soluble guanylate cyclase
View Patent ↗The present application relates to novel azabicyclic compounds, processes for their preparation, their use alone or in combinations for the treatment and/or prevention of diseases, and their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.
1. A compound of formula (I)
L-CH 2 -M-Q (I),
in which
L is phenyl substituted up to twice by halogen,
M is (d)
* is the point of linkage to the —CH 2 -L group,
** is the point of linkage to the Q group,
A is N,
B and D are each CH, and
Q is an unsaturated 6-membered heterocycle having up to four heteroatoms, which may be substituted up to four times by —NH 2 , or a salt, an N-oxide, or salt of an N-oxide thereof.
2. 6-[1-(2-Fluorobenzyl)-1H-imidazo[2,1-c][1,2,4]triazol-3-yl]-1,3,5-triazine-2,4-diamine:
or a salt, an N-oxide, or salt of an N-oxide thereof.
3. 6-[1-(2-Fluorobenzyl)-1H-[1,2,4]triazolo[3,4-c][1,2,4]triazol-3-yl]-1,3,5-triazine-2,4-diamine:
or a salt, an N-oxide, or salt of an N-oxide thereof.
4. A pharmaceutical composition comprising a compound of claim 1 , 2 , or 3 in combination with an inert, non-toxic pharmaceutically suitable excipient.
5. The pharmaceutical composition of claim 4 further comprising an active ingredient selected from the group consisting of organic nitrates, NO donors, cGMP-PDE inhibitors, agents having antithrombotic activity, agents lowering blood pressure, and agents altering lipid metabolism.